Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990;31(3):182-6.
doi: 10.1007/BF01744734.

Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin

W H De Jong  1 , E C De Boer, A P Van der Meijden, P Vegt, P A Steerenberg, F M Debruyne, E J Ruitenberg
Affiliations

Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin

W H De Jong et al. Cancer Immunol Immunother. 1990.

Abstract

Urine samples were obtained from patients with superficial bladder cancer after immunotherapy with bacillus Calmette-Guérin (BCG). The patients were repeatedly (once a week for 6 consecutive weeks) treated with intravesical administration of approximately 5 X 10(8) culturable particles of BCG. Some patients received more than six BCG instillations. The urine samples were investigated for the presence of interleukin-2 (IL-2) in an in vitro bioassay using a murine cytotoxic T cell line (CTTL-16) that shows IL-2-dependent growth. Preliminary experiments indicated the presence of inhibitory factors in the urine. This inhibitory activity was abolished after 24 h dialysis. In a neutralization assay with both polyvalent and monoclonal anti-(human IL-2) antibody it was demonstrated that there was indeed IL-2 in the urine samples. In 8 of 11 patients the presence of IL-2 in the urine was demonstrated. The IL-2 production was directly related to the BCG administration as samples obtained just before the BCG instillation were always negative. In IL-2-positive samples a maximum level of IL-2 was observed between 2 h and 6 h after the BCG instillation. In urine samples obtained 24 h after the BCG IL-2 was not detected. In most patients the urine became positive after the third or fourth PCG instillation.

PubMed Disclaimer

References

    1. Böhle A, Nowc C, Ulmer A, Musehold J, Flad F. Detection of urinary Il-1, IL-2, and TNF after intravesical BCG therapy. In: Debruyne FMJ, editor. Symposium on New Trends in Urology, September 13–16 1989 Abstract book. Nijmegen, The Netherlands: University of Nijmegen Medical School; 1989. p. 40.
    1. Coe JE, Felman JD. Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder. Immunology. 1966;10:127. - PMC - PubMed
    1. Debruyne FMJ, Van der Meijden AMP, Geboers ADH, Franssen MPH, Van Leeuwen MJW, Steerenberg PA, De Jong WH, Ruitenberg EJ. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of a randomized prospective trial. Urology [Suppl] 1988;31:20. - PubMed
    1. De Jong WH, Steerenberg PA, Kreeftenberg JG, Tiesjema RH, Kruizinga W, Van Noorle-Jansen LM, Ruitenberg EJ. Experimental screening of BCG preparations produced for cancer immunotherapy. Safety and immunostimulating and antitumor activity of four consecutively produced batches. Cancer Immunol Immunother. 1984;17:18. - PMC - PubMed
    1. De Jong WH, Teppema JS, Wagenaar Sj Sc, Paques M, Steerenberg PA, Ruitenberg EJ. Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinoma. Virchows Arch [B] 1986;50:249. - PubMed

LinkOut - more resources